arrow_back Trending Legislation
Share share

The INSULIN Act of 2026: Capping Costs at $35 and Increasing Access

This act lowers insulin costs for patients by setting a $35 monthly price cap and removing deductibles for selected products. It also creates new support systems for uninsured individuals and speeds up the market entry of cheaper generic alternatives.
Key points
Caps out-of-pocket costs for a 30-day insulin supply at $35 starting in 2027.
Prohibits insurance plans from applying deductibles to essential insulin products.
Establishes a pilot program in 10 states to provide $35 insulin for uninsured citizens.
Creates a 24/7 national hotline and resource center to help patients find affordable medication.
Speeds up the approval process for cheaper generic and biosimilar insulin products.
Requires pharmacy managers to pass all manufacturer rebates to health plans to lower overall costs.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Introduced
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
INSULIN Act of 2026
Print number: S 4189
Sponsor: Sen. Shaheen, Jeanne [D-NH]
Process start date: 2026-03-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about The INSULIN Act of 2026: Capping Costs at $35 and Increasing Access

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 4189.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2026-03-25.

What are the main provisions?

Key points include:

  • Caps out-of-pocket costs for a 30-day insulin supply at $35 starting in 2027.
  • Prohibits insurance plans from applying deductibles to essential insulin products.
  • Establishes a pilot program in 10 states to provide $35 insulin for uninsured citizens.
  • Creates a 24/7 national hotline and resource center to help patients find affordable medication.
  • Speeds up the approval process for cheaper generic and biosimilar insulin products.
  • Requires pharmacy managers to pass all manufacturer rebates to health plans to lower overall costs.

What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Shaheen, Jeanne [D-NH].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-04-13.

Analysis and Potential Impact of S 4189

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Economy Benefits